4cell Therapies S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-09-01
Share capital
3,172,432.10 PLN
Activity description

4cell Therapies is a company that develops CAR-T therapies for treating solid tumors, including challenging cases like pancreatic cancer, and hematological cancers such as leukemia and lymphoma. The company conducts research and development in Poland, utilizing advanced genetic engineering to create antigen receptors that target and destroy cancer cells. They also optimize production processes to meet GMP standards, ensuring scalability for future commercialization.

Registered address
ul. Bojkowska 59 C, 44-100 Gliwice, Poland
Email
Phone
Electronic delivery address
AE:PL-61449-60062-HDUSJ-16

Financials

Revenue history (in k)

Financial insight

  • The statement flags a going concern risk. Sprawozdanie finansowe zostało sporządzone przy założeniu kontynuacji działalności w dającej się przewidzieć przyszłości tj. w szczególności przez okres co najmniej 12 miesięcy od dnia bilansowego mimo, że Spółka poniosła w bieżącym okresie stratę netto w wysokości minus 2 726 951,55 zł, co zwiększyło straty lat ubiegłych. Na dzień podpisania sprawozdania finansowego Zarząd zauważa występowanie niepewności co do możliwości kontynuowania działalności na skutek braku środków finansowych, w porównaniu do potrzeb na najbliższy rok obrotowy, trwający od stycznia 2026 do grudnia 2026. Zarząd podejmuje działania opisane w nocie 38 do sprawozdania finansowego, co uzasadnia przyjęcie założenia kontynowania działalności.

Filing timeliness

Financial statements were filed on time, on average 23 days early. All were audited by a statutory auditor.

  • 202513/07/2026
  • 202408/07/2025
  • 202312/07/2024
  • 202213/02/2023
  • 202125/01/2022
  • 202002/02/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Scientific research and development1,429 / 1,943
Top 74%
City · Gliwice1,859 / 2,104
Top 88%
Voivodeship · Śląskie29,277 / 33,148
Top 88%
Country · Poland260,403 / 297,069
Top 88%

Results vs industry

Revenue
This companyUSD 9.12kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -684.82kMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 591.53kMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 832.67kMedianUSD 134.71kAverageUSD 3.04m

Authorized Representatives

Paweł Marcin Wiśniewski age 46 – President of the Management Board

Manner of representation

1. The submission of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy. 2. If the management board is a one-person management board, one member of the management board is authorized to submit declarations on behalf of the company.

Supervisory board

Krzysztof Artur Zbarski age 54 – Supervisory Board Member
Piotr Maciej Kamiński age 58 – Supervisory Board Member
Maciej Paweł Kolon age 43 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2013-02-07.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

European Funds

ProjectEU co-financing
Development of a new, effective and highly specific breast cancer therapy with potentially low toxicity, based on the patented DOS47 technology platform, which modifies the tumor microenvironment and immune response by changing pH.
$3.2M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Onconick sp. z o.o.
Biolabic sp. z o.o.
Cannamedai S.A.
DR Joanna Sanford sp. k.
Inventro S.A.
Cellis sp. z o.o.
Nanovelos S.A.
Oncotherics Poland S.A.
Bioinfo Capital sp. z o.o.
Synerga.Fund S.A.

Change history

DateEvent
2026-09-10Share capital increase
2026-05-15Share capital increase
2023-12-27Share capital increase
2021-06-07Name change
2020-10-27Share capital increase

FAQ

Last updated: 2026-09-10